- Home
- SKLZ vs KYTX Comparison
SKLZ vs KYTX Comparison
Compare SKLZ & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKLZ
- KYTX
- Stock Information
- Founded
- SKLZ 2012
- KYTX 2018
- Country
- SKLZ United States
- KYTX United States
- Employees
- SKLZ N/A
- KYTX N/A
- Industry
- SKLZ EDP Services
- KYTX
- Sector
- SKLZ Technology
- KYTX
- Exchange
- SKLZ Nasdaq
- KYTX NYSE
- Market Cap
- SKLZ 80.3M
- KYTX 92.1M
- IPO Year
- SKLZ N/A
- KYTX 2024
- Fundamental
- Price
- SKLZ $5.61
- KYTX $2.11
- Analyst Decision
- SKLZ Buy
- KYTX Buy
- Analyst Count
- SKLZ 2
- KYTX 5
- Target Price
- SKLZ $10.75
- KYTX $18.80
- AVG Volume (30 Days)
- SKLZ 54.1K
- KYTX 203.0K
- Earning Date
- SKLZ 05-08-2025
- KYTX 05-16-2025
- Dividend Yield
- SKLZ N/A
- KYTX N/A
- EPS Growth
- SKLZ N/A
- KYTX N/A
- EPS
- SKLZ N/A
- KYTX N/A
- Revenue
- SKLZ $95,466,000.00
- KYTX N/A
- Revenue This Year
- SKLZ N/A
- KYTX N/A
- Revenue Next Year
- SKLZ $18.77
- KYTX N/A
- P/E Ratio
- SKLZ N/A
- KYTX N/A
- Revenue Growth
- SKLZ N/A
- KYTX N/A
- 52 Week Low
- SKLZ $3.54
- KYTX $1.78
- 52 Week High
- SKLZ $7.48
- KYTX $17.55
- Technical
- Relative Strength Index (RSI)
- SKLZ 68.62
- KYTX 48.82
- Support Level
- SKLZ $5.00
- KYTX $1.92
- Resistance Level
- SKLZ $5.44
- KYTX $2.38
- Average True Range (ATR)
- SKLZ 0.32
- KYTX 0.17
- MACD
- SKLZ 0.09
- KYTX 0.02
- Stochastic Oscillator
- SKLZ 84.31
- KYTX 41.30
About SKLZ Skillz Inc.
Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.